Objectives
We aimed to study the association of fibroblast growth factor-23 (FGF-23) with
conventional cardiovascular risk factors in hemodialysis (HD) patients.
Patients and methods
This is a cross-sectional study, which was carried out on 90 HD patients.
Demographic data were recorded in predefined data sheets. The blood samples
for FGF-23 and other laboratory variables were collected and measured using the
standard methods. The results and their relationships with FGF-23 were analyzed.
Results
In our study, there were insignificant correlations between FGF-23 and all clinical
cardiovascular variables apart from a significant positive correlation between FGF-
23 and systolic blood pressure (r=−0.546, P=0.004). Multivariate analysis failed to
show any significant association between FGF-23 and systolic blood pressure
(B=0.749, T=1.659, P=0.067).
Conclusion
Multiple linear regression analysis failed to show any significant association
between FGF-23 and other conventional cardiovascular risk factors. We
recommend using FGF-23 as an independent risk factor of cardiovascular
morbidity and mortality, and searching for agents that control its level in HD
patients.